---
title: "OKYO Pharma is all set to commence a clinical trial for dry eye treatment in the US"
publisher: "Share Talk"
author: "sharetalk"
published: "2023-04-25T06:55:16+00:00"
modified: "2023-04-25T06:55:16+00:00"
date: 2023-04-25
canonical: "https://www.share-talk.com/okyo-pharma-is-all-set-to-commence-a-clinical-trial-for-dry-eye-treatment-in-the-us/"
category: "Healthcare"
categories: ["Healthcare", "Pharmaceutical"]
tags: ["biotechnology", "Bloomberg", "diseases", "Dr. Gary Jacob", "Dr. Napoleone", "dry eye", "inflammatory", "life sciences", "NASDAQ", "New York Medical College", "OKYO", "OKYO Pharma", "Share Talk", "Willy Simon"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# OKYO Pharma is all set to commence a clinical trial for dry eye treatment in the US

**Published:** April 25, 2023
**Author:** sharetalk
**Categories:** Healthcare, Pharmaceutical
**Tags:** biotechnology, Bloomberg, diseases, Dr. Gary Jacob, Dr. Napoleone, dry eye, inflammatory, life sciences, NASDAQ, New York Medical College, OKYO, OKYO Pharma, Share Talk, Willy Simon
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

### Activation of First Clinical Trial Site in the U.S

**OKYO Pharma Ltd,** a biotech company focused on ophthalmology, has announced the activation of its first clinical trial site in the United States for phase II trials of its dry eye disease treatment, OK-101.

**About OK-101**

OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry eye disease.

OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.

The trial will be multi-centred, randomised, double-blinded, and placebo-controlled, and the first patient is expected to be accepted within two weeks.

With approximately 700 million people worldwide suffering from this chronic ocular condition, the drug candidate aims to address a significant unmet need in the multi-billion-dollar dry eye disease market. Using membrane-anchored-peptide technology, OK-101 has demonstrated anti-inflammatory and pain-reducing activities in mouse models with dry eye disease and corneal neuropathic pain.

The candidate drug molecule includes a lipid anchor to combat washout and enhance time on the eyeball. **Gary Jacob, CEO of OKYO Pharma**, anticipates that clinical evaluation will be completed by year-end.

---

**Original URL:** https://www.share-talk.com/okyo-pharma-is-all-set-to-commence-a-clinical-trial-for-dry-eye-treatment-in-the-us/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*